New PET tracer lights up pancreatic tumors in early trial
NCT ID NCT06129422
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new imaging agent called NMK89 in 10 people with pancreatic cancer. NMK89 is designed to attach to a protein (MUC5AC) found on these cancer cells and show up on PET scans. The main goal was to check if it is safe and how well it helps doctors see the tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BAMF Health
Grand Rapids, Michigan, 49503, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?
- Can a pill rouse the immune system against pancreatic cancer?